# Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

> **NCT02022917** · PHASE2 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 22 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02022917
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2021-01
- **Final completion:** 2021-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-01-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02022917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02022917, "Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02022917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*